OTCMKTS:RNLXD Renalytix (RNLXD) Stock Price, News & Analysis $1.29 0.00 (0.00%) As of 05/28/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Renalytix Stock (OTCMKTS:RNLXD) Get Renalytix alerts:Sign Up Key Stats Today's Range$1.24▼$1.2950-Day Range$1.29▼$1.2952-Week Range$3.13▼$8.09Volume16,853 shsAverage Volume2,432 shsMarket Capitalization$11.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Renalytix plc is a healthcare technology company focused on improving the detection and management of chronic kidney disease. The company develops diagnostic tools that combine blood-based biomarkers with artificial intelligence and machine-learning algorithms to assess a patient’s risk of kidney disease progression. Its principal product, KidneyIntelX, is designed to help identify patients with diabetic kidney disease who face an elevated risk of rapid progression toward kidney failure. The test is intended to support earlier intervention and more personalized care by providing clinicians with risk information that can complement standard laboratory measures and clinical assessment. Renalytix was established in the United Kingdom and developed its technology through work involving the Icahn School of Medicine at Mount Sinai in the United States. Its activities have focused primarily on the U.S. and U.K. markets, with the company pursuing clinical, regulatory, and commercial partnerships to expand adoption of its kidney disease testing platform. James McCullough has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Receive RNLXD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNLXD Stock News HeadlinesRenalytix Plc (RNLXY)December 27, 2025 | finance.yahoo.comRenalytix PLC ADRDecember 23, 2025 | barrons.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Renalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comSee More Headlines RNLXD Stock Analysis - Frequently Asked Questions How have RNLXD shares performed this year? Renalytix's stock was trading at $3.62 at the beginning of the year. Since then, RNLXD stock has decreased by 64.4% and is now trading at $1.29. How were Renalytix's earnings last quarter? Renalytix Plc (OTCMKTS:RNLXD) announced its earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.70 million. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include NVIDIA (NVDA), Invitae (NVTA), Pinterest (PINS), SEA (SE), Block (XYZ), Opendoor Technologies (OPEN) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/14/2023Today10/16/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolOTCMKTS:RNLXD CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees100Year Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.21 Quick Ratio1.17 Sales & Book Value Annual Sales$3 million Price / Sales3.76 Cash FlowN/A Price / Cash FlowN/A Book Value($1.06) per share Price / Book-1.22Miscellaneous Outstanding Shares8,740,000Free Float7,822,000Market Cap$11.27 million OptionableOptionable Beta2.63 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:RNLXD) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
